Gsk3B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
GSK3B (Glycogen Synthase Kinase 3 Beta) is a serine/threonine-protein kinase that plays a central role in energy metabolism, neuronal cell development, and body pattern formation. It is one of the most actively studied kinases in neurodegeneration research due to its pivotal role in tau hyperphosphorylation.
The GSK3B gene encodes a protein kinase that is ubiquitously expressed but particularly abundant in the brain. GSK3β is a key downstream target of the PI3K/Akt signaling pathway and is inhibited by phosphorylation at Ser9. Dysregulation of GSK3β activity contributes to the pathogenesis of Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.
| Attribute | Value |
|---|---|
| Gene Symbol | GSK3B |
| Chromosome | 3q13.33 |
| Protein Size | 420 amino acids |
| Molecular Weight | ~47 kDa |
| Expression | Brain (highest), liver, muscle, kidney |
GSK3β is a proline-directed serine/threonine kinase that phosphorylates over 100 substrates, including:
GSK3β is a major tau kinase implicated in AD pathogenesis. Hyperactive GSK3β phosphorylates tau at multiple sites (Ser199, Ser202, Thr205, Ser396, Ser404), promoting neurofibrillary tangle formation. GSK3β also contributes to amyloid-β production and synaptic dysfunction.
In PD, GSK3β promotes α-synuclein phosphorylation at Ser129, enhancing its aggregation. GSK3β also contributes to dopaminergic neuron death through mitochondrial dysfunction and oxidative stress.
| Drug/Compound | Mechanism | Status |
|---|---|---|
| Lithium | Direct GSK3β inhibitor | Approved for bipolar disorder |
| Tideglusib | Selective GSK3β inhibitor | Phase II trials for AD |
| SB 216763 | ATP-competitive inhibitor | Preclinical |
| AZD1080 | Brain-penetrant inhibitor | Discontinued |
GSK3β is expressed throughout the brain with highest levels in:
Current research focuses on developing brain-penetrant GSK3β inhibitors with improved safety profiles, understanding isoform-specific functions (GSK3α vs GSK3β), and identifying downstream substrates that mediate specific disease phenotypes.
The study of Gsk3B Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.